Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:LARK)
:LARK
LARK Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.27 - kr3.06
Previous CloseN/A
VolumeN/A
Average Volume (3M)56.88K
Market Cap
kr46.73M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 13, 2025Dividend Yield8.62%
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,801,197
10 Day Avg. Volume94,967
30 Day Avg. Volume56,875
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
LARK FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was kr1.27 and its highest was kr3.06 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is kr46.73M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Aug 22, 2025 which is in 27 days.
How were CombiGene AB’s earnings last quarter?
Currently, no data Available
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Notavailable dividend of kr1.93 which represents an annual dividend yield of 8.62%. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in SE:LARK
Company Description
CombiGene AB
CombiGene AB (COMBI) is a biotechnology company focused on the development of innovative gene therapy solutions to treat severe life-altering diseases. Operating within the healthcare sector, CombiGene specializes in leveraging cutting-edge genetic technologies to create therapies that address unmet medical needs. The company's core products are centered around gene therapy treatments, particularly in the areas of neurological disorders and metabolic diseases.
Technical Analysis
ExpreS2ion Biotech Holding AB
―
Modus Therapeutics Holding AB
―
OncoZenge AB
―
Spago Nanomedical AB
―
Sprint Bioscience AB
―